Amylyx Pharmaceuticals, Inc. (AMLX) has 85 open-market insider trades by 16 insiders since 2022. Over the last six months insiders net sold $2.9M. The most active filer is Justin B. Klee, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10% Owner | — | 2 | $127.1M | 2022-09-09 |
| Morningside Venture Investments Ltd via Bihua Chen | 10% Owner | — | 9 | $43.5M | 2023-08-15 |
| Justin B. Klee | CEO | — | 14 | $8.3M | 2026-09-10 |
| Joshua B. Cohen | CEO | — | 14 | $8.3M | 2026-09-10 |
| ALS Invest 1 B.V. | 10% Owner | — | 1 | $2.5M | 2022-07-06 |
| James M. Frates | CFO | — | 10 | $2.2M | 2026-09-10 |
| George M. Milne Jr. | Dir | — | 3 | $2.1M | 2026-01-12 |
| Patrick D. Yeramian | — | — | 2 | $1.8M | 2024-01-09 |
| Gina Mazzariello | CLO | — | 13 | $1.1M | 2026-09-10 |
| Camille L. Bedrosian | — | — | 7 | $974K | 2026-09-10 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| George M. Milne Jr. | Director | Sell | $831K | 2026-10-05 |
| Camille L. Bedrosian | — | Sell | $325K | 2026-09-10 |
| Gina Mazzariello | CLO | Sell | $310K | 2026-09-10 |
| Justin B. Klee | CEO | Sell | $980K | 2026-09-10 |
| James M. Frates | CFO | Sell | $350K | 2026-09-10 |
| Joshua B. Cohen | CEO | Sell | $981K | 2026-09-10 |
Companies that share insiders with AMLX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Gina Mazzariello | CLO | Sell | $539K | 2026-07-09 |
| Karen Firestone | Director | Buy | $51K | 2026-05-21 |
| Camille L. Bedrosian | Chief Medical Officer | Sell | $94K | 2026-03-02 |
| James M. Frates | CFO | Sell | $115K | 2026-03-02 |
| Joshua B. Cohen | CEO | Sell | $424K | 2026-03-02 |
| Justin B. Klee | CEO | Sell | $424K | 2026-03-02 |
| Gina Mazzariello | CLO | Sell | $99K | 2026-03-02 |
| Gina Mazzariello | CLO | Sell | $48K | 2026-02-23 |
| James M. Frates | CFO | Sell | $52K | 2026-02-02 |